Prior analyses of global data from real world use of flash glucose monitoring have associated frequency of scanning with greater time in range and lower mean glucose, glucose variability, and hypoglycemia. These analyses did not include data from North America as flash glucose monitoring became available in late 2017. The objective of this follow-up analysis is to focus on real world outcomes in patients using flash glucose monitoring in Canada. A server collected anonymized data from patients whose flash glucose readers are uploaded (by patient or health care professional). Data from patients within Canada was analyzed through September 2018 (approximately 1 year). To understand the relationship between time in range and glucose variability with monitoring frequency, individuals were divided into 10 equal sized groups based on scanning frequency. Average ± SE time in range (glucose 70 mg/dL - 180 mg/dL [3.9 mmol/L - 10.0 mmol/L]) and time in glucose ≤ 54 mg/dL (∼3.0 mmol/L) was calculated for each group.

This analysis includes 15,424 readers, 95,103 sensors, and 108 million glucose measurements with an average of 12 scans per day. Patients in the lowest scanning frequency decile (3.7 scans per day) spent 12.6 ± 0.14 hours in range and 28.8 ± 1.2 minutes with a glucose ≤ 54 mg/dL. Patients in the highest scanning frequency decile (29.2 scans per day) spent 16.6 ± 0.12 hours in range and 22.1 ± 1.0 minutes with a glucose ≤ 54 mg/dL.

Real-world data from Canada demonstrates that higher frequency of scanning is associated with increased time in range and decreased hypoglycemia. This analysis is consistent with prior analyses and suggests that patients with diabetes who scan to obtain their glucose more frequently derive greater benefit than patients who scan less frequently.


L. Berard: Advisory Panel; Self; Eli Lilly and Company. Consultant; Self; Abbott, Ascensia Diabetes Care, AstraZeneca, Bayer AG, Becton, Dickinson and Company, Janssen Pharmaceuticals, Inc., LifeScan Canada, Mylan, Novo Nordisk Inc., Sanofi. Research Support; Self; Montmed Inc. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc. N. Virdi: Employee; Self; Abbott, Proteus Digital Health. Stock/Shareholder; Self; Johnson & Johnson. T. Dunn: Employee; Self; Abbott Laboratories.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at